Physician profile
John J Duque
NPI 1295710747
$1,273.44
in general payments reported to CMS, 2019-2025
13 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $36.87 · 2021: $258 · 2022: $179 · 2023: $198 · 2024: $103 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.68 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $242.39 | 2019 | |
| Braintree Laboratories, INC. | $139.25 | 2019-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $114.35 | 2022-2025 | Ocaliva |
| Redhill Biopharma INC. | $111.41 | 2021-2023 | Talicia |
| Endogastric Solutions, INC | $87.76 | 2023 | Esophyx |
| Abbvie INC. | $69.75 | 2022-2024 | Linzess, Creon |
| Celltrion USA INC. | $63.91 | 2024-2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $61.72 | 2019-2020 | |
| Evoke Pharma, INC. | $30.42 | 2024 | |
| Novo Nordisk INC | $30.12 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $20.57 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $16.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Duque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.